Elranatamab Induces Responses in Many Patients With Resistant Multiple Myeloma in Phase II Trial
2023-02-25Read more
MagnetisMM-32
Phase 3 Clinical Trial Comparing the Safety and Effectiveness of Elranatamab Versus Commonly Used Combination Regimens in Participants with Relapsed/Refractory Multiple Myeloma
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.